Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

OGT develops transformative constitutional NGS panel

publication date: Jan 21, 2020
 | 
author/source: Oxford Gene Technology

ogt-develops-transformative-constitutional-ngs-panel


Oxford Gene Technology (OGT), A Sysmex Group Company, has developed a breakthrough targeted NGS panel for constitutional cytogenetics research.

The new CytoSure™ NGS panel—launching early in 2020—will combine the strengths of microarrays and NGS to deliver a comprehensive all-in-one assay. The new panel, in conjunction with OGT’s popular Interpret analysis software facilitates the accurate and confident detection of loss of heterozygosity (LOH), mosaicism and copy number variants (CNVs), in addition to those more traditionally assayed by NGS, single nucleotide variants (SNVs) and insertions/deletions (indels).

Featuring the most up-to-date content for Intellectual Disability (ID) and Developmental Delay (DD), the new targeted NGS panel and Interpret software enable users to detect even small (single exon) CNVs accurately — something that is has been challenging with NGS and hence a major step forward for the technology.

Emma Shipstone, EVP, Marketing at OGT commented, “We have developed our CytoSure NGS panel to meet the increasing desire of labs to transition from microarrays to NGS and obtain as much information as possible from a single assay. NGS technologies have traditionally struggled with CNV detection, but thanks to OGT’s panel design expertise and advanced software algorithms, we have overcome these challenges, delivering exceptional CNV data that exhibits excellent concordance with arrays. The results are very easy to interpret, with our highly intuitive software allowing a seamless transition to NGS for ID/DD analysis, in what has historically been the domain of the array. Ahead of launch early next year, our early access collaborators are telling us that the data quality speaks for itself and more than meets their requirements.”

Dr John Anson, CEO of OGT also added, “Moving with and anticipating market needs, we’re strengthening our CytoSure brand in constitutional cytogenetics with the development of our first CytoSure NGS panel. OGT, as a part of Sysmex, is committed to developing our assay portfolio, delivering the highest quality solutions to meet the real-world challenges faced by cytogeneticists. CytoSure NGS represents a real leap forward in NGS technology, demonstrating OGT’s capability—as experts in hybridisation—to lead the global market in this field.”

CytoSure™ For Research Use Only; Not for Use in Diagnostic procedures

For more information please visit https://www.ogt.com/cytosure-ngs

 

learn more about cytosure-ngs

more news from OGT




 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners